When a doctor performs a stem cell transplant, the cells almost always come from one of three places: bone marrow, circulating blood, or umbilical cord blood. These are the only sources used in treatments that have met the standard of evidence required for routine medical care. Each source has its own collection process, its own risks, and its own best uses.
That answer covers the established side of stem cell medicine. A separate and much larger industry exists around unproven stem cell products, and the sources those clinics use are different. Knowing the difference matters if you or someone you love is considering treatment.
Where Do Doctors Get Stem Cells For Treatment?
For approved treatments, doctors get stem cells from a donor’s bone marrow, from a donor’s bloodstream after medication moves stem cells out of the marrow, or from donated umbilical cord blood.
The cells in all three sources are called hematopoietic stem cells. Hematopoietic means they build blood. These cells live mainly in bone marrow and have one main job: producing the body’s supply of red blood cells, white blood cells, and platelets for a person’s entire life.
Here is the part people often miss. A stem cell transplant is not a treatment for the disease itself. It is a way to rebuild a person’s blood and immune system after high-dose chemotherapy or radiation has wiped out the diseased or damaged bone marrow. The new cells take over blood production from scratch.
Bone marrow
This is the original source, and the method behind the first successful transplants in the late 1960s. The donor receives anesthesia, and the doctor inserts a needle into the back of the hip bone to draw out marrow. The procedure collects a small fraction of the donor’s total marrow, which the body replaces within weeks. Donors typically feel sore for a few days afterward.
Peripheral blood
This is now the most common source for adult transplants. The donor takes injections of a growth factor drug for several days. That drug pushes hematopoietic stem cells out of the marrow and into the bloodstream. The blood is then run through a machine that separates out the stem cells and returns the rest to the donor.
This approach avoids anesthesia and generally collects more cells in one session. It does carry a trade-off. Research has found that donors who receive growth factor injections have a higher chance of chronic graft-versus-host disease in the recipient compared with marrow donation. That is a real consideration doctors weigh when choosing a source.
Umbilical cord blood
After a baby is born, blood left in the umbilical cord and placenta can be collected and frozen. This blood is rich in hematopoietic stem cells. Cord blood is donated, tested, and stored in public banks, where it is available to any patient who matches.
Cord blood has two practical advantages. It does not require a perfect donor match, and it can be used immediately because it is already stored. Its main limitation is cell count. A single cord blood unit contains far fewer stem cells than a marrow or blood donation, which can slow engraftment and makes it harder to use in larger adults.
Why do stem cell transplants work at all?
The transplanted cells find their way to the bone marrow, settle in, and begin producing blood cells. This process is called engraftment.
Engraftment does not happen overnight. It usually takes a few weeks before the new cells start making enough white blood cells, and longer before platelet and red cell counts recover. During that window, the patient is at high risk of infection and needs close monitoring.
There is a second effect that matters in cancer treatment. When the donor’s immune cells recognize the patient’s remaining cancer cells as foreign, they attack them. This is called the graft-versus-tumor effect, and it is one reason transplants can eliminate disease that chemotherapy alone could not.
That same immune reaction can turn against healthy tissue. Graft-versus-host disease happens when donor immune cells attack the patient’s body, most often the skin, gut, and liver. It is one of the most serious complications of transplant and a major reason the procedure is reserved for conditions where the potential benefit clearly outweighs the risk.
What conditions are treated with stem cell transplants?
Hematopoietic stem cell transplants are established treatment for a defined set of diseases, mostly involving blood, bone marrow, and the immune system.
- Leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia
- Lymphomas such as Hodgkin and non-Hodgkin lymphoma
- Multiple myeloma
- Severe aplastic anemia and other bone marrow failure disorders
- Thalassemia and sickle cell disease
- Certain inherited immune deficiencies
- Some solid tumors, including certain testicular cancers and neuroblastoma
The list is specific for a reason. Each of these conditions has been studied in clinical trials, and the evidence supports transplant as a treatment option for at least some patients within each group. That is not true for most other diseases.
Autologous vs. allogeneic: two different donor paths
Doctors divide transplants into two types based on whose cells are used, and the source of the cells often follows from that choice.
| Type | Cell source | Common uses | Main risk |
|---|---|---|---|
| Autologous | The patient’s own cells, collected before treatment | Multiple myeloma, lymphoma | Cancer cells may be collected along with stem cells |
| Allogeneic | A matched donor, often a sibling or unrelated volunteer | Leukemia, aplastic anemia, sickle cell disease | Graft-versus-host disease |
In an autologous transplant, the patient’s own cells are collected, frozen, and returned after high-dose treatment. Because the cells are the patient’s own, there is no risk of graft-versus-host disease. There is also no graft-versus-tumor effect, which is why this approach is less useful for diseases where the immune attack matters.
In an allogeneic transplant, cells come from a donor. This is where matching matters. Doctors compare a set of proteins on the surface of cells called HLA markers. A close match lowers the odds of both rejection and graft-versus-host disease. Siblings have the best chance of matching, but most patients do not have a matched sibling. Registries of volunteer donors exist specifically to fill that gap.
Where do unproven stem cell clinics get their cells?
Clinics selling unproven stem cell treatments most often use cells taken from a patient’s own fat tissue or bone marrow, then processed and injected back into the body, sometimes the same day.
The problem is what those cells actually are. Fat tissue contains cells that can develop into fat, bone, or cartilage. They are not blood-forming stem cells, and there is no established evidence they can rebuild damaged organs, repair a spinal cord, or treat conditions like Parkinson’s disease, multiple sclerosis, or autism.
The FDA has stated that many of these products require regulatory approval and has warned that some clinics are operating outside the law. Serious harms have been documented, including infections, tumors, blindness, and death following unapproved injections into the eye, spine, and bloodstream.
One clarification that gets lost in this debate: not every experimental use is illegitimate. Legitimate stem cell research happens at academic medical centers under institutional review board oversight, with informed consent, safety monitoring, and published results. The difference is not whether a treatment is new. The difference is whether it is being studied properly or sold directly to patients as if it were already proven.
How are donors matched to patients?
Donors are matched to patients through HLA typing, a blood test that identifies proteins on the surface of cells.
These proteins tell the immune system which cells belong to the body and which do not. The closer the match, the lower the chance the donor’s immune cells will attack the patient’s tissues, and the lower the chance the patient’s body will reject the graft.
Doctors look first at siblings, who have about a one in four chance of being a full match. If no sibling matches, they search registries of volunteer donors, which now include millions of people worldwide. For patients without a match, cord blood or a partially matched donor can be an option, and transplant centers have developed approaches that make these alternatives work better than they once did.
If you want to know where the stem cells for a treatment you are considering came from, ask directly. A legitimate program will tell you the source, the cell type, whether the treatment is part of a clinical trial, and what is known about its risks. If those answers are vague, that itself is information.
Frequently Asked Questions
Where do doctors get stem cells for bone marrow transplants?
They collect them from a donor’s bone marrow, from the donor’s bloodstream after growth factor injections, or from donated umbilical cord blood. All three sources contain hematopoietic stem cells, the cells that rebuild blood and the immune system.
Can you use your own stem cells for a transplant?
Yes, in what is called an autologous transplant, your own cells are collected and stored before high-dose treatment, then returned to you afterward. This approach is common for multiple myeloma and lymphoma but does not work for every condition.
Are stem cells from fat tissue the same as bone marrow stem cells?
No. Fat tissue contains cells that can form fat, bone, or cartilage, not blood-forming stem cells. No clinical evidence currently confirms that fat-derived cells can treat the diseases that bone marrow transplants are approved for.
How long does it take for transplanted stem cells to work?
Engraftment usually begins within a few weeks, with white blood cell counts recovering first and platelets and red cells following later. Patients need close monitoring during that period because infection risk is high until the new cells are producing enough immune cells.
